Stocks of ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) traded higher last session on Wall Street, down -3.89% to $0.70.
IPA stock price is now 41.26% away from the 50-day moving average and 42.41% away from the 200-day moving average. The market capitalization of the company currently stands at $32.10M.
With the price target of $9, H.C. Wainwright recently initiated with Buy rating for ImmunoPrecise Antibodies Ltd (NASDAQ: IPA). On October 25, 2021, The Benchmark Company recently initiated its ‘Buy’ rating on the stock quoting a target price of $12
A total of 13.30% of the company’s stock is owned by insiders.
During the past 12 months, ImmunoPrecise Antibodies Ltd has had a low of $0.27 and a high of $1.08. As of last week, the company has a debt-to-equity ratio of 0.51, a current ratio of 2.32, and a quick ratio of 2.11. The fifty day moving average price for IPA is $0.49662 and a two-hundred day moving average price translates $0.49263 for the stock.
The latest earnings results from ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) was released for 2025-01-31. The net profit margin was -190.81% and return on equity was -121.65% for IPA. The company reported revenue of $4.33 million for the quarter, compared to $4.6 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.04 percent.
